SCHEMBL4868481

SCHEMBL4868481

Cc1nc(C)c(-c2ccc3cc(-c4c(-c5ccccc5)c5sc(C(=O)O)cc5n4CC(=O)Nc4nccs4)ccc3n2)s1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.39
MAPT P10636 3/20 0.39
HPGD P15428 2/20 0.39
SMN1; SMN2 Q16637 3/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
PKM P14618 2/20 0.36
HSD17B10 Q99714 1/20 0.36
SIRT2 Q8IXJ6 1/20 0.36
MEN1 O00255 7/20 0.36
KMT2A Q03164 7/20 0.36
HTT P42858 4/20 0.36
CYP1A2 P05177 4/20 0.35
CYP3A4 P08684 4/20 0.35
CYP2C19 P33261 3/20 0.35
ALDH1A1 P00352 3/20 0.35
CYP2C9 P11712 3/20 0.35
KDM4E B2RXH2 2/20 0.35
POLB P06746 2/20 0.35
ALOX12 P18054 1/20 0.35
RECQL P46063 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4877231 0.89 LMNA (0.41) LMNAMAPTHPGDSMN1; SMN2L3MBTL1
SCHEMBL4876042 0.88 KDM4E (0.36) HSD17B10HTTALDH1A1KDM4E
SCHEMBL4868472 0.87 KCNH2 (0.34) LMNAPKMHSD17B10HTTCYP1A2
SCHEMBL4872723 0.87 MAPT (0.40) LMNAMAPTHPGDSMN1; SMN2L3MBTL1
SCHEMBL4868462 0.86 MAPT (0.40) LMNAMAPTHPGDSMN1; SMN2L3MBTL1
SCHEMBL4878159 0.83 KCNH2 (0.34)
SCHEMBL3931430 0.83 KDM4E (0.35) MAPTHPGDSMN1; SMN2HSD17B10HTT
SCHEMBL4875218 0.83 MAPT (0.40) LMNAMAPTHPGDSMN1; SMN2L3MBTL1
SCHEMBL4876347 0.81 GRIN2B (0.39) HPGDSMN1; SMN2HSD17B10MEN1KMT2A
SCHEMBL4876223 0.81 GRIN2B (0.39) MAPTHPGDSMN1; SMN2HSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051384-A1 ANTIVIRAL AGENTS EIF2AK2, MAVS, ZC3HAV1 LMNA 3337/4885MAPT 4372/4885HPGD 2973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.